Latest market price
13.06
+0.15+1.16%
OverviewShort InterestFilings
CBIOQT22Crescent Biopharma, Inc.·NASDAQ
13.06+1.16%
TA
Loading chart...
Signal & projected range
Short-squeeze setupHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
QURE+3.92%$23.87RARE+2.02%$16.63NUVB+2.18%$4.69TRAX+2.86%$46.34NTLA+1.72%$11.86ABSI+3.20%$10.00URGN+0.12%$34.40MAZE+6.19%$32.25
Snapshot
Index—P/E—EPS (ttm)-7.58Insider Own—Shs Outstand37.14MPerf Week-1.58%
Market Cap479.53MForward P/E—EPS next Y-2.91Insider Trans2.76%Shs Float18.51MPerf Month-6.31%
Enterprise Value308.53MPEG—EPS next Q-0.67Short Float23.87%Perf Quarter-17.18%
Income-163.00MP/S39.96EPS this Y—Short Ratio12.10Perf Half Y-27.77%
Sales12.00MP/B2.94EPS next Y—ROA-89.18%Short Interest4.42MPerf YTD10.12%
Book/sh4.39P/C2.79EPS next 5Y—ROE-97.77%52W High27.41 -52.35%Perf Year2.43%
Cash/sh4.63P/FCF—EPS past 3/5Y—ROIC-102.29%52W Low8.72 49.77%Perf 3Y-88.64%
Dividend Est.—EV/EBITDA—Sales past 3/5Y— 1.92%Gross Margin—Volatility8.15% 8.02%Perf 5Y-93.20%
Dividend TTM—EV/Sales25.71EPS Y/Y TTM—Oper. Margin-1417.74%ATR (14)1.08Perf 10Y-97.94%
Dividend Ex-DateJan 13, 2023Quick Ratio9.66Sales Y/Y TTM—Profit Margin-1371.51%RSI (14)43.42Recom2.29
Dividend Gr. 3/5Y—Current Ratio9.66EPS Q/Q84.99%SMA20-1.21%Beta1.38Target Price36.00
Payout0.00%Debt/Eq0.01Sales Q/Q—SMA50-15.52%Rel Volume0.46Prev Close12.91
Employees44LT Debt/Eq0.01EarningsNov 05SMA200-17.79%Avg Volume347.07KPrice13.06
IPO DateJan 10, 2014Option/ShortYes / YesEPS/Sales Surpr.-0.58% —Net Debt/EBITDA—Volume159,531Change1.16%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-19-26ReiteratedUBS$36
Oct-06-26UpgradeHC Wainwright & Co.Neutral → Buy$36
Jun-01-26DowngradeHC Wainwright & Co.Buy → Neutral
Feb-26-26ReiteratedStifel NicolausBuy$32 → $29
Jan-28-26InitiatedPiper SandlerOverweight$35
Jan-21-26InitiatedGuggenheimBuy$35
Dec-04-25ReiteratedStifel NicolausBuy$28 → $32
Aug-25-25InitiatedJefferiesBuy$26
Jul-26-24DowngradeTD CowenBuy → Hold
May-06-24DowngradeHC Wainwright & Co.Buy → Neutral
Latest News· Times ET
Today
Today04:15PM
Crescent Biopharma Announces Grants of Inducement Awardsglobenewswire.com
Nov-02-26
Nov-02-2607:30AM
Crescent Biopharma to Present at November Investor Conferencesglobenewswire.com
Oct-19-26
Oct-19-2608:07AM
Crescent Biopharma (NASDAQ:CBIO) Stock Rating Reaffirmed as Buy by HC Wainwrightdefenseworld.net
02:19AM
HC Wainwright & Co. Reiterates Buy on Crescent Biopharma, Maintains $36 Price TargetBenzinga
Oct-15-26
Oct-15-2604:15PM
Crescent Biopharma Announces Clinical Pipeline Momentum, including Enrolling Patients in Standard of Care Chemotherapy Combination Cohorts of Global Phase 1/2 ASCEND Trial of CR-001, a PD-1 x VEGF Bispecific Antibody, and Initiation of Additional ADC Combination Studies with CR-001globenewswire.com
Oct-06-26
Oct-06-2604:15PM
Crescent Biopharma Announces Grants of Inducement Awardsglobenewswire.com
02:18AM
HC Wainwright & Co. Upgrades Crescent Biopharma to Buy, Announces $36 Price TargetBenzinga
Oct-05-26
Oct-05-2607:30AM
Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumorsglobenewswire.com
Sep-29-26
Sep-29-2604:05AM
12 Health Care Stocks Moving In Tuesday's Pre-Market SessionBenzinga
Sep-25-26
Sep-25-2604:15PM
Crescent Biopharma Announces Grants of Inducement Awardsglobenewswire.com
11:46AM
The Nascent Crescent Biopharma Thesis: One Year Later And Things Are SteadySeekingAlpha
Sep-21-26
Sep-21-2604:39AM
Insider Selling: Crescent Biopharma (NASDAQ:CBIO) Insider Sells $11,098.00 in Stockdefenseworld.net
04:39AM
Insider Selling: Crescent Biopharma (NASDAQ:CBIO) CEO Sells $28,819.00 in Stockdefenseworld.net
04:39AM
Insider Selling: Crescent Biopharma (NASDAQ:CBIO) Insider Sells $11,151.70 in Stockdefenseworld.net
04:39AM
Insider Selling: Crescent Biopharma (NASDAQ:CBIO) CFO Sells $10,167.20 in Stockdefenseworld.net
Company

Crescent Biopharma, Inc. is a biotechnology firm dedicated to the research and development of novel cancer therapies. Its investigational portfolio notably includes CR-001, a proprietary bispecific antibody engineered to simultaneously target PD-1 and VEGF pathways for the treatment of solid tumors. The company's pipeline further comprises CR-002 and CR-003. Crescent Biopharma also maintains a strategic alliance with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., focusing on the joint advancement and commercialization of oncology therapeutics, encompassing innovative combination approaches. The company's operations are headquartered in Waltham, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue121100—————
Cost of Goods Sold Incl. D&A
0000—————
Gross Profit121100—————
Selling, General and Administrative Excl. Other30251619—————
Research and Development1521382820—————
Other Operating Expense-2060—————
Operating Income-168-153-50-39—————
Interest Expense0210—————
Unusual Expense
—————————
Non-Operating Income (Expense)5322—————
Net Income Before Taxes-163-152-49-37—————
Income Taxes2200—————
Consolidated Net Income-163-154-49-37—————
Net Income From Continuing Operations-165-154-49-37—————
Net Income-163-154-49-37—————
EPS (Recurring)-7.58-14.78-63.22-58.25—————
EPS (Basic, Before Extraordinaries)-7.58-14.78-63.22-58.25—————
EPS (Diluted)-7.58-14.78-63.22-58.25—————
EBITDA-163-150-44-39—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio33.7410.78———————
Gross Margin100.00100.00———————
Operating Margin-1,400.00-1,390.91———————
Net Margin-1,358.33-1,400.00———————
Shares Outstanding311011—————
Market Capitalization40511925236—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$29.69$23.82$17.96$12.10$6.23● Close Price0.00M4.56M9.12M13.68M18.24MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Brumm Joshua TChief Executive OfficerSep 18 '26Sale16.717,837130,956271,765Sep 18
McNeill JonathanPresident and COOSep 18 '26Sale16.713,83964,150134,588Sep 18
Brumm Joshua TChief Executive OfficerSep 16 '26Sale17.901,61028,819279,602Sep 18
McNeill JonathanPresident and COOSep 16 '26Sale17.9073113,085138,427Sep 18
Scalzo Richard WilliamChief Financial OfficerSep 16 '26Sale17.9056810,16719,730Sep 18
Bispham Barbara HarlinOfficerSep 16 '26Sale17.9062011,09818,710Sep 18
Lynch RyanOfficerSep 16 '26Sale17.902404,29613,631Sep 18
Pinkas JanChief Scientific OfficerSep 16 '26Sale17.9065811,77821,581Sep 18
Im Ellie EunkyungChief Medical OfficerSep 16 '26Sale17.9062311,15221,446Sep 18
Fairmount Funds Management LLCDirector, 10% OwnerJul 16 '26Buy8.971,379,34712,375,5513,601,316Jul 20
Pinkas JanChief Scientific OfficerJun 22 '26Sale17.991,28823,17122,239Jun 23
Scalzo Richard WilliamChief Financial OfficerJun 22 '26Sale17.991,11220,00520,298Jun 23
Bispham Barbara HarlinOfficerJun 22 '26Sale17.991,21821,91219,330Jun 23
Im Ellie EunkyungChief Medical OfficerJun 22 '26Sale17.991,21921,93022,069Jun 23
McNeill JonathanPresident and COOJun 22 '26Sale17.9920,549369,677139,158Jun 23
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.